Overview

A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge

Status:
Recruiting
Trial end date:
2023-08-07
Target enrollment:
Participant gender:
Summary
The purpose of the study is to characterize the inflammatory response to lipopolysaccharide (LPS; molecules that contains fats and carbohydrates) in the presence of a targeted immune pathway modulator.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Adalimumab